Funding for this research was provided by:
National Institutes of Health/National Cancer Institute (R01CA231952)
Received: 18 February 2022
Accepted: 23 February 2022
First Online: 22 March 2022
: This study protocol was reviewed and approved by the Institutional Review Board at Moffitt Cancer Center in Tampa, FL (USA) on June 13, 2019. IRB# 00000971. The most recent continuing review was completed on June 16, 2021 (Protocol Version 2)<i>.</i> Informed consent will be obtained from participants. We have a waiver of written documentation of informed consent. Therefore, oral consent will be obtained from participants consenting via phone or in person. Additionally, if a participant reads the consent themselves via the REDCap database consent screen, this will constitute acknowledgment of consent (no e-signature). All data will be kept confidential and stored in a secured location on an institutional server, which is backed up daily. Only certain members of the study staff or others designated by the MPIs will have access to the study data.
: Not applicable because we will not collect or videos of participants in this study. Additionally, no details on individuals are reported within the manuscript.
: The authors declare that they have no competing interests.